Aleva Neurotherapeutics

Executive Summary

Aleva Neurotherapeutics is a Swiss commercial-stage medical device company pioneering Directional Deep Brain Stimulation (DBS) systems for neurological disorders. Founded in 2008 as a spin-off from EPFL, the company's flagship product, the directSTIM™ system, received CE marking and is designed to improve therapeutic outcomes, minimize side effects, and reduce surgical revisions in Parkinson's disease. By enabling precise directional stimulation of targeted brain regions, Aleva's technology addresses key limitations of conventional DBS, offering a differentiated solution in the growing neuromodulation market. The company is headquartered in Lausanne, Switzerland, and remains privately held. The global DBS market is expanding, driven by an aging population and increasing prevalence of Parkinson's disease and other movement disorders. Aleva's competitive advantage lies in its proprietary directional lead technology, which has the potential to capture significant share from established players. Key milestones include CE mark approval and initial commercialization in Europe. Near-term focus is on expanding clinical indications, such as essential tremor and obsessive-compulsive disorder, while pursuing regulatory clearance in the United States. With a robust intellectual property portfolio and a seasoned team, Aleva is well-positioned to capitalize on the shift toward personalized neuromodulation therapies.

Upcoming Catalysts (preview)

• H2 2026FDA IDE approval for US pivotal trial of directSTIM system70% success
• 2027Expansion into new indications (essential tremor, OCD) with clinical data readouts60% success
• H1 2027Strategic partnership or distribution agreement for European market expansion65% success